RHHBY - Roche Holding AG
| Previous Close | 29.95 |
| Open | 29.98 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's Range | 29.98 - 30.27 |
| 52 Week Range | 26.30 - 32.42 |
| Volume | 478,731 |
| Avg. Volume | 1,280,906 |
| Market Cap | 207.111B |
| Beta | 0.43 |
| PE Ratio (TTM) | 23.79 |
| EPS (TTM) | 1.27 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.08 (3.84%) |
| Ex-Dividend Date | 2018-03-15 |
| 1y Target Est | 33.33 |
- Zacks•4 days ago
Agenus (AGEN) Delivering Well on Its Pipeline Candidates
We have issued an updated report on Agenus (AGEN) highlighting updates on its pipeline candidates.
- Zacks•6 days ago
Roche's (RHHBY) Xolair Gets Breakthrough Therapy Status
Genentech's, a subsidiary of Roche (RHHBY), allergy drug, Xolair, gets Breakthrough Therapy designation in the United States for the prevention of severe food allergic reactions.
- Business Wire•6 days ago
FDA Grants Breakthrough Therapy Designation for Xolair (Omalizumab) for Food Allergies
OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Xolair® (omalizumab) for the prevention of severe allergic reactions following accidental exposure to one or more foods in people with allergies. Breakthrough Therapy Designation is designed to expedite the development and review of medicines intended to treat serious or life-threatening diseases, and to help ensure people have access to them through FDA approval as soon as possible.
- Bloomberg•8 days ago
Sensors to Smartphones Bring Patent Wars to Diabetes Monitoring
Diabetes treatment has evolved since Mary Fortune was diagnosed in 1967 and hospitalized because there was no reliable way monitor her blood sugar. Fortune and other diabetics are benefiting from an explosion in technology and innovation, from under-the-skin sensors that eliminate the need for painful finger pricks, to smartphone alerts when glucose levels rise too high. For glucose monitors alone, the number of published patent applications has grown steadily for a decade and has accelerated significantly since 2015, according to an analysis by the research firm Patinformatics.
- Zacks•9 days ago
Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales
Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.
- InvestorPlace•11 days ago
Protagonist Stock Jumps 58% After Re-Review of Test Results
The mouth-watering 58% rise in shares of Protagonist Therapeutics (NASDAQ:PTGX) on Monday should interest biotech investors. At a market cap of $236.2 million, experienced biotech investors will expect higher than normal volatility. On Monday, Protagonist announced that it secured $22 million in equity financing through the sale of 2.75 million shares.
- Zacks•11 days ago
Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus
Prothena (PRTA) posts wider-than-expected loss in the second quarter. With the failure of lead drug, NEOD001, the focus is now mainly on its mid-stage candidate, prasinezumab.
Market Realist•12 days agoRecent Product Approvals Bode Well for Bristol-Myers Squibb
Bristol-Myers Squibb (BMY) has key licensing arrangements with Biogen (BIIB) and Roche Holding (RHHBY). It out-licensed the exclusive rights to develop and commercialize BMS-986168 to Biogen in the second quarter of 2017. This compound is in development for the treatment of progressive supranuclear palsy.
- Zacks•13 days ago
Is a Beat in Store for Horizon Pharma (HZNP) in Q2 Earnings?
During the second-quarter earnings call, Horizon Pharma (HZNP) will focus on the performance of business units along with that of Actimmune and Krystexxa and update on teprotumumab's development.
- Investor's Business Daily•17 days ago
Can Regeneron Stock Hit $400 For The First Time This Year?
Regeneron Pharmaceuticals on Thursday reported adjusted income of $5.45 per share on $1.61 billion in sales for the second quarter.
- Moody's•17 days ago
Moody's: US drug makers face heightened pricing pressure as regulatory risks pick up steam
Recent decisions by some of the major US branded drug manufacturers not to institute price increases at mid-year, or for the remainder of 2018, reflect the heightened prospect of increasing government regulation on drug pricing, Moody's Investors Service says in a new report. "The decision to forego customary price increases will raise pricing pressure on US branded drug makers," said Michael Levesque, a Moody's Senior Vice President. For the time being, there remains a large difference between gross and net price increases, since drug companies pay rebates to pharmacy benefit managers and rebates are rising, Levesque says.
Market Realist•17 days agoMerck’s Keytruda Witnessed Solid Growth in First Half of 2018
How Is Merck Positioned in H2 2018? In Q2 2018, Merck’s (MRK) Keytruda generated revenues of $1.67 billion compared to $881.0 million in Q2 2017, reflecting ~89% YoY growth. In Q2 2018, in the US and international markets, Keytruda generated revenues of $959.0 million and $707.0 million, respectively, compared to $556.0 million and $325.0 million in Q2 2017, reflecting ~73% and ~118% YoY growth.
- Zacks•17 days ago
Exelixis (EXEL) Earnings Beat on Strong Cabometyx in Q2
Exelixis (EXEL) posts better-than-expected results for the second quarter, propelled by strong demand for Cabometyx. A milestone payment from Ipsen also boosts sales and earnings.
- Zacks•19 days ago
What's in Store for Epizyme (EPZM) This Earnings Season?
Investors are likely to remain focused on Epizyme's (EPZM) lead candidate, tazemetostat, in the second quarter earnings call.
- GlobeNewswire•19 days ago
Roche Purchases Shares in Tender Offer for FMI
OTCQX: RHHBY) and Foundation Medicine, Inc. (FMI) today announced that Roche`s wholly owned subsidiary 062018 Merger Subsidiary, Inc. has accepted for payment all shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of Foundation Medicine not already owned by Roche or its affiliates, at a price of $137.00 per share in cash. The tender offer expired at 12:00 midnight, Eastern Time, at the end of the day on 30 July 2018 and was not extended.
- PR Newswire•19 days ago
Roche to showcase how labs are driving change across health networks to address PAMA and other challenges at AACC 2018 Clinical Lab Expo
- Featured labs address challenges by streamlining processes, reducing costs and optimizing operations while ensuring delivery of care - Digital tools and data-based analytics facilitate operational and ...
- Zacks•20 days ago
What's in Store for Immune Design (IMDZ) in Q2 Earnings?
We expect Immune Design (IMDZ) to focus on the progress of its pipeline candidates in the second quarter earnings call.
- PR Newswire•20 days ago
Roche's cobas HPV Test receives FDA approval for first-line cervical cancer screening using SurePath preservative fluid
OTCQX: RHHBY) announced today that it has received U.S. Food and Drug Administration (FDA) approval for the cobas® HPV Test to be used as the first-line screening test for cervical cancer in women 25 and older using cervical specimens collected in SurePath preservative fluid, a collection medium commonly used for Pap tests. The Roche test is now the only Human Papillomavirus (HPV) test approved for use as a primary (first-line) screening test with both SurePath and ThinPrep PreservCyt Solution, the two types of liquid media used to collect samples for the vast majority of Pap or HPV tests in the U.S. With this FDA decision, the cobas HPV Test is now approved for all of the cervical cancer screening indications that are supported by professional society guidelines—primary screening in women 25 and older, reflex (follow-up) testing of unclear Pap test results in women 21 and older and co-testing with a Pap test in women 30 and older—with both of the primary collection media types.
- Zacks•23 days ago
AbbVie's (ABBV) Q2 Earnings Beat Estimates, 2018 View Up
AbbVie's (ABBV) Q2 earnings top estimates with revenues marginally beating the same. Revenues increase on strong sales growth of Humira, Imbruvica and Mavyret.
- Zacks•23 days ago
Roche (RHHBY) 1H18 Revenues Up Y/Y on Solid New Drug Sales
Roche's (RHHBY) performance in the first half is buoyed by solid strength in new drugs like Ocrevus. The increase in guidance is impressive as well.
- The Wall Street Journal•24 days ago
[$$] Roche Confirms Restructuring That Could Affect Dozens
AG on Thursday raised its annual guidance for the second straight time this year as it posted results that beat expectations, but confirmed it would restructure its pharmaceuticals division to consist of two organizations. Restructuring plans at the Swiss pharmaceutical giant could affect dozens of employees world-wide as the company seeks to decentralize its operations in a bid to become more competitive, according to a person familiar with the matter. Roche told around 350 managers about the restructuring in its pharmaceuticals division at the beginning of the month, when it laid out plans for regional offices to shut down in an effort to decentralize, removing regional intermediaries, the person said.
- CNBC Videos•4 days ago
Roche a strategic player in the big pharma M&A battlegrou...
Brian McGee, principal at Novasecta, discusses mergers and acquisitions activity in the pharmaceutical industry.
Yahoo Finance Video•16 days ago‘Christoper Robin’ versus ‘Mission Impossible: Fallout’ at the box office
Winnie the Pooh is returning to theaters today in ‘Christopher Robin.’ The highly-anticipated movie, however, might fall short of stealing the number one spot from ‘Mission Impossible: Fallout’ at the box office. Yahoo Finance’s Alexis Christoforous, Dan Howley and Julia La Roche discuss.
Yahoo Finance Video•16 days agoExclusive: Walmart tests grocery-picking robots
Walmart is testing grocery-picking robots at a store in New Hampshire. Yahoo Finance’s Alexis Christoforous speaks with Julia La Roche and Daniel Howley about what it means.
Yahoo Finance Video•19 days agoYahoo Finance Live: Market Movers - Jul 31st, 2018
Yahoo Finance's LIVE stock market coverage and analysis.
